Welcome to our dedicated page for Alnylam Pharmaceuticals news (Ticker: ALNY), a resource for investors and traders seeking the latest updates and insights on Alnylam Pharmaceuticals stock.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) is at the forefront of RNA interference (RNAi) therapeutics, pioneering a transformative class of medicines aimed at treating and potentially curing a wide range of diseases. Founded in 2002 and based in Cambridge, MA, Alnylam has translated Nobel Prize-winning science into five commercial products: ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), and Leqvio (inclisiran), developed and commercialized in partnership with Novartis. These breakthrough therapeutics address conditions such as hATTR amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1, and hypercholesterolemia.
Alnylam is dedicated to expanding its pipeline with several investigational medicines in late-stage development, focusing on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases. The company’s commitment to sustainable innovation is reflected in its robust product pipeline and strategic collaborations with industry leaders like Roche and Regeneron.
Financially, Alnylam reported robust growth in 2023 with $1.24 billion in global net product revenues, a reflection of its strong commercial execution across its therapeutic products. The company maintains a strong cash position, bolstered by upfront fees from research partnerships and milestone achievements.
Alnylam is also dedicated to corporate responsibility, with initiatives aimed at reducing greenhouse gas emissions, promoting diversity and inclusion in clinical trials, and expanding global health equity through its Alnylam Challengers program. The company’s environmental impact data is third-party verified, underscoring its commitment to transparency and sustainability.
Looking ahead, Alnylam aims to sustain its leadership in RNAi therapeutics with the anticipated release of topline results from the HELIOS-B Phase 3 study and the continued development of promising candidates like zilebesiran for hypertension and mivelsiran for Alzheimer’s disease. For more details on Alnylam’s people, science, and pipeline, visit www.alnylam.com.
Alnylam Pharmaceuticals reported positive topline results from its HELIOS-B Phase 3 study for vutrisiran, an RNAi therapeutic for ATTR amyloidosis with cardiomyopathy (ATTR-CM).
Statistically significant reductions in all-cause mortality and recurrent cardiovascular events were observed in both the overall population and monotherapy population. Specifically, the study showed a 28% reduction in the overall population and a 33% reduction in the monotherapy population.
Secondary endpoints also demonstrated significant improvements, including a 36% reduction in all-cause mortality in the overall population and a 35% reduction in the monotherapy population. Other key measures such as the 6-minute walk test, Kansas City Cardiomyopathy Questionnaire, and NYHA Class also showed clinical benefits.
The study confirmed vutrisiran's safety profile, with adverse events comparable between the vutrisiran and placebo groups. Alnylam plans to file a U.S. Supplemental New Drug Application and proceed with global regulatory submissions.
Alnylam Pharmaceuticals, Inc. issued its 2023 Corporate Responsibility Report, showcasing its commitment to environmental sustainability, patient access, and health equity. The report includes new data on environmental impact, expanded partnerships for diversity and inclusion in clinical trials, and the extension of the Alnylam Challengers global health equity initiative. Additionally, the report discloses employee demographic data and results of a pay equity analysis.
Alnylam Pharmaceuticals reported strong first quarter 2024 financial results with Global Net Product Revenues of $365 million, reflecting a 32% Year-Over-Year Growth. The company achieved positive results in the Zilebesiran Hypertension Program, initiated Phase 2 studies, and remains on track to report Topline Results from Vutrisiran's Phase 3 Study. Alnylam reiterated its 2024 Financial Guidance with expected combined Net Product Revenues of $1,400 million to $1,500 million.
Medison Pharma and Alnylam Pharmaceuticals have announced an expansion of their partnership to commercialize RNAi therapeutics in additional markets, including LATAM and APAC, to provide innovative therapies to patients across the globe. This partnership aims to accelerate access to Alnylam's life-saving therapies in multiple regions under one global alliance.
FAQ
What is the current stock price of Alnylam Pharmaceuticals (ALNY)?
What is the market cap of Alnylam Pharmaceuticals (ALNY)?
What is Alnylam Pharmaceuticals known for?
What products has Alnylam commercialized?
What diseases do Alnylam’s products treat?
What are the recent financial achievements of Alnylam?
Who are Alnylam’s key strategic partners?
What environmental initiatives has Alnylam undertaken?
What is the Alnylam Challengers program?
What are some key pipeline developments for Alnylam?
Where is Alnylam Pharmaceuticals headquartered?
How can I learn more about Alnylam Pharmaceuticals?
